Trico

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trico

Quick Facts

Property Description
Active Ingredient Metronidazole
Origin Synthetic compound
Pharmacological Class Nitroimidazole Antimicrobial Agent
Primary Action Dual antibacterial and antiprotozoal activity
Dosage Forms Oral, Injectable, and Topical preparations

What Type of Medicine is Trico?

Trico is a medication primarily defined by its sole active ingredient, Metronidazole, which is classified as a synthetic nitroimidazole antimicrobial agent. This classification signifies its specific chemical structure and its unique ability to combat infectious microorganisms. Trico is not merely a traditional antibiotic; its dual pharmacological action makes it highly effective against certain types of anaerobic bacteria and specific single-celled protozoa. This broad spectrum of action against two distinct classes of pathogens is why the medication is clinically recognized for its essential role in treating infections where oxygen levels are low.


The Composition and Forms of Trico

Trico is a single-ingredient product, with its core composition centered on the active substance, Metronidazole, combined with inert pharmaceutical bases or excipients necessary for manufacturing. The medication is presented in various high-level dosage forms to accommodate different administration needs. These forms include common oral formulations (such as tablets or capsules), sterile injectable solutions for intravenous use, and various topical preparations (like gels or creams) for focused application. The availability of multiple forms ensures that the route of administration—be it systemic (oral, intravenous) or localized (topical)—can be chosen to effectively deliver the active ingredient.


How Does Trico Generally Function?

Trico is classified as a prodrug, meaning it requires chemical activation after administration to become therapeutically effective. This unique activation is triggered only within the low-oxygen (anaerobic) environment of susceptible bacteria and protozoa, providing a targeted approach to treatment. Once activated, the compound damages the organism's DNA and nucleic acid structure. This selective disruption prevents the pathogens from reproducing and functioning, leading to their swift destruction. This action establishes Trico as a potent agent for eliminating specific infection-causing organisms at their source.

Regulatory References

  1. NIH: Metronidazole Drug Information

What side effects are possible with Trico?

Possible Side Effects and Safety Information

The official safety profile of Trico (Metronidazole) is structured according to regulatory classifications, detailing adverse reactions based on frequency and affected body systems. These classifications distinguish between common, expected reactions and rare, serious events documented in official prescribing information.

Adverse Reaction Scope

Category Description
Common Effects Reactions frequently listed in regulatory documents include nausea, headache, and an unpleasant metallic taste (taste disturbance) [NIH MedlinePlus overview of Metronidazole]. Gastrointestinal disturbances like diarrhea and abdominal pain are also noted in official sources.
Serious Adverse Reactions Regulatory labels document clinically significant risks affecting the central nervous system, such as Encephalopathy, Convulsive Seizures, and the potential for Aseptic Meningitis. Other serious, but rare, documented events include Severe Cutaneous Adverse Reactions (SCARs) and severe Hepatotoxicity [FDA Label, Metronidazole Injection].
Systemic Effects Adverse reactions are grouped by physiological systems including the Nervous System (e.g., peripheral neuropathy), Gastrointestinal Tract, and Blood and Lymphatic System (e.g., leukopenia).

Safety Considerations and Restrictions

The official labeling includes constraints for specific populations and exposure patterns. Use is explicitly contraindicated in patients with Cockayne Syndrome due to the risk of fatal acute hepatic failure [EMA SmPC]. Monitoring for adverse reactions is recommended for individuals with severe hepatic impairment or end-stage renal disease (ESRD) due to potential drug accumulation. Prolonged administration of Trico is associated with reports of persistent Peripheral Neuropathy, and clinical observation is advised if treatment extends beyond ten days [FDA Label, FLAGYL]. The regulatory text also mandates the avoidance of alcohol due to the documented risk of a disulfiram-like reaction.

Overdose and Emergency Response

Trico Overdose and When to Seek Help

Official regulatory documentation defines the Trico (Metronidazole) overdose profile based on its documented clinical manifestations. Symptoms reported in overdose cases include specific gastrointestinal signs, namely nausea and vomiting. More critically, neurological involvement is documented through the presence of ataxia, characterized by a lack of muscle coordination.

Overexposure is associated with severe neurotoxic outcomes. The regulatory label notes that effects such as seizures and peripheral neuropathy have been reported following high-dose exposure. The presence of these severe or potentially life-threatening manifestations dictates the necessity of an immediate response.

Urgent medical help is required upon the suspicion of a massive overdose or the manifestation of any severe neurological sign. This necessity is further underscored by the mandated management approach:

Official Overdose Management Regulatory Statement
Antidote Availability No specific antidote is known.
Mandated Treatment Management should consist of symptomatic and supportive therapy.

The official protocol dictates that treatment focuses entirely on addressing the clinical symptoms and providing life support, as there is no specific agent to reverse the effects. Therefore, the onset of severe neurotoxicity serves as the explicit trigger for seeking immediate professional care.

Therapeutic Uses of Trico

What Trico Treats: Main Uses and Benefits

Trico is an antimicrobial agent that is generally used for managing infections caused by specific protozoal parasites and anaerobic bacteria, organisms that thrive in low-oxygen environments. The therapeutic application is relevant in contexts involving heightened systemic burden from these particular pathogens.


Targeted Management of Infectious Symptoms

The medication is commonly used to help manage symptoms across conditions like Trichomoniasis, Amebiasis, and Bacterial Vaginosis (BV). It is applied when symptoms create noticeable physiological strain, such as severe intestinal distress (dysentery), abnormal vaginal discharge, or odor. It is also used to treat gastrointestinal and reproductive system infections caused by these organisms. Trico's use may also assist with maintaining functional stability in the presence of more serious anaerobic bacterial infections, including abdominal abscesses and septicemia.

The core benefit relates to providing symptomatic relief across key domains, which helps ease the overall symptom load and supports improved comfort during periods of heightened symptoms.

“The primary goal of Trico is to provide supportive relief during difficult episodes by managing the symptoms that cause infection-related distress.”

This application extends to specific localized inflammatory states, such as the skin lesions of Rosacea and certain oral/dental infections. Furthermore, Trico plays a role in managing symptoms across therapeutic areas involving heightened responses by being applied during surgical prophylaxis. This use supports general well-being by assisting with maintaining stability when symptoms are more noticeable.


Quick Fact: Relief for Anaerobic Symptoms
Primary Indication Group Infections from Anaerobic Bacteria and Protozoal Parasites
Key Symptom Cluster Discharge, odor, fever, pain, and gastrointestinal distress
Common Scenarios Gynecological infections, abscesses, and surgical support

Regulatory References

  1. NIH MedlinePlus overview of Metronidazole

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Trico

Official regulatory documents define specific populations who are eligible for Trico (Metronidazole) and those for whom use is contraindicated or restricted.


Contraindicated Populations

Trico is strictly prohibited for individuals with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Use is also forbidden in patients with Cockayne Syndrome due to the risk of severe hepatotoxicity. Furthermore, the medicine must not be used by patients who have consumed alcohol or disulfiram within a specified time frame.


Restricted and Conditional Use

Eligibility is limited by certain physiological states. A 50% dosage reduction is officially recommended for patients with severe hepatic impairment (Child-Pugh C). Caution is advised for patients with Central Nervous System diseases or a history of blood dyscrasias. Monitoring for metabolite accumulation is recommended for patients on hemodialysis and older adults (over 70 years).


Age and Reproductive Status

Use is generally established for adults and some pediatric patients. Trico is not recommended during the first trimester of pregnancy. For nursing mothers, official guidance often recommends discontinuing breastfeeding for a period following high-dose therapy. The safety of topical forms is not established in children.

What should I know about interactions with other medicines?

Trico Interactions with other medicines and products

The official regulatory profile for Trico (Metronidazole) documents specific pharmacokinetic and pharmacodynamic interaction patterns with a range of other medicinal products and substances.

Interaction Classification Interacting Agents and Official Outcome
Mandatory Contraindications Disulfiram: Prohibited for co-administration; Trico should not be given if Disulfiram was taken within the last two weeks, due to the risk of psychotic reactions. Alcoholic Beverages / Propylene Glycol: Consumption is prohibited during therapy and for at least three days following the last dose, based on the documented risk of a disulfiram-like reaction (e.g., headache, flushing).
Exposure Alterations Warfarin and Coumarin Anticoagulants: Trico potentiates the anticoagulant effect, officially resulting in the prolongation of prothrombin time. Lithium and Busulfan: Trico has been reported to increase the serum concentrations of these medications, raising the risk of toxicity. Cimetidine: This drug may increase the blood concentration of Metronidazole by slowing its clearance.
Clearance Reduction Co-administration with enzyme-inducing agents such as Phenytoin, Phenobarbital, Rifampin, or Carbamazepine can accelerate Trico’s metabolic clearance, leading to lower plasma concentrations and potentially reduced effectiveness. Additionally, Cholestyramine can reduce Trico's systemic absorption.

Population-Specific Accumulation Official labeling notes that patients with severe hepatic impairment metabolize Trico slowly, which results in the accumulation of the active drug and its metabolites. Similarly, patients with End-Stage Renal Disease exhibit documented elevated plasma concentrations of Trico’s metabolites.

Mechanism of Action

Trico functions as a chemically inert prodrug, meaning its activation is dependent on the host microbial cell itself. This activation is highly selective, occurring only when the drug encounters the low-redox potential found within the electron transport systems of obligate anaerobic bacteria and certain protozoa. Specific microbial electron carriers, such as Ferredoxin, reduce the drug's nitro group ( NO2), generating a short-lived, highly reactive nitro radical anion . This mechanism explains the drug's selectivity, as high oxygen levels prevent this reduction, rendering the mechanism ineffective against aerobic organisms.

The highly reactive radical anion and subsequent toxic intermediates directly inflict damage upon the pathogen’s genetic material. The active metabolites covalently bind to the microbial DNA and nucleic acids, leading to strand breakage and structural destabilization. This molecular disruption prevents the organism from synthesizing essential proteins or replicating its genetic code. The molecular disruption results in the cessation of viability and cell death of the targeted anaerobic pathogens, which is a direct consequence of the drug’s selective cytotoxic mechanism.

Dosage and Administration Information

Trico (fenofibrate) is an oral medication taken as part of a comprehensive management program that includes diet, exercise, and weight control to treat elevated cholesterol and triglyceride levels. The drug may be taken with or without food, as a single dose, at any time of day, but should be administered exactly as prescribed by a healthcare professional.

Administration and Dosage

The Trico tablets must be swallowed whole and should not be crushed, broken, dissolved, or chewed. Your doctor will determine the appropriate dose based on your specific lipid disorder and kidney function.

  • Primary Hypercholesterolemia or Mixed Dyslipidemia: The usual starting and maintenance dose is 145 mg once daily.
  • Severe Hypertriglyceridemia: The initial dose ranges from 48 mg to 145 mg once daily. The maximum recommended dose is 145 mg daily.
  • Patients with Renal Impairment: A reduced starting dose of 48 mg once daily may be required.

Missed Doses and Monitoring

If a dose is missed, patients should not take an extra dose or double the dose to catch up. The patient should simply resume treatment with the next scheduled dose.

Treatment response is typically evaluated as early as 4 to 8 weeks after starting the medication or a dosage change. It's important to have frequent medical tests, even without symptoms, to determine the drug’s effectiveness. If you are taking a bile acid-binding resin (e.g., cholestyramine), you should take Trico at least 1 hour before or 4 to 6 hours after the resin to prevent reduced absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trico

Evidence for Use in Protozoal and Gynecological Infections (Trichomoniasis and BV)

Trico was evaluated in research concerning certain infections where specific single-celled organisms thrive, primarily focusing on Trichomoniasis and Bacterial Vaginosis (BV). The research for these conditions includes Randomized Controlled Trials (RCTs), comparative trials, and large-scale Systematic Reviews that gather data from multiple sources. These trials examined outcomes related to physical discomfort and systemic imbalance, such as the measurement of parasite or bacteria clearance and the resolution of common symptoms like discharge and irritation.

Research on Trichomoniasis

Studies conducted during periods of increased symptom activity have explored Trico’s use in symptomatic and asymptomatic individuals. Research primarily focused on two key measurements: Microbiological Cure, which monitors the eradication of the T. vaginalis parasite, and Clinical Cure, which assesses the resolution of symptoms. Studies reported measurements of clearance within the observed groups. However, research highlights that variations in measurements of clearance were observed depending on the specific dosing regimen used.

Research on Bacterial Vaginosis

The research on Trico exploring its use in BV involves trials that compared various formulations, including oral and topical applications, and different treatment durations. Trials documented measurements of initial clinical and microbiological clearance across both oral and topical formulations. However, findings consistently indicate that the rates of recurrence in the months following treatment varied and were observed across all regimens studied.

Evidence for Use in Systemic Anaerobic Infections and Amebiasis

Trico was evaluated in research exploring temporary physiological imbalance in patients with serious infections caused by anaerobic bacteria, as well as in parasitic infections like Amebiasis. The evidence base includes RCTs, comparative trials, and high-quality observational cohorts. Research explored measurements of infection signs in these study populations, particularly when used alongside other agents. Data show patterns related to combination therapy—Trico is nearly always studied with a second drug, which limits information regarding its effect when used alone.

What is Still Uncertain About Trico Research

A primary area of uncertainty is the increasing documentation of drug resistance, particularly in T. vaginalis strains, which continues to challenge the consistency of measured clearance rates. Furthermore, due to its historical role as a necessary component in combination regimens for systemic infections, the unique effect of Trico when used alone for acute conditions is not fully established in contemporary research.

Frequently Asked Questions (FAQ)

Common questions about Trico (FAQ)


Q: Does Trico cure the condition or just manage symptoms?

Studies indicate that Trico works by killing the specific infectious organisms it is designed to target, which is referred to as having antimicrobial activity. Research on this medicine reports measurements of microbiological cure, which is the successful eradication of the parasite or bacteria. Its documented action is to eliminate the infectious organism rather than only addressing symptoms.


Q: Is it normal to feel [vague side effect like dizziness/tiredness] after starting Trico?

Official information lists dizziness and trouble sleeping (insomnia) as possible side effects. The regulatory label also documents more serious central nervous system events that may occur. If these or other central nervous system symptoms are experienced, official information indicates that concerns should be addressed with a healthcare professional.


Q: What kind of foods should be avoided when using Trico?

Official labeling requires the avoidance of all alcoholic beverages and products containing propylene glycol during treatment and for a specified time afterward. The product information does not detail other specific food restrictions and generally states that Trico may be taken with or without food.


Q: How long does it take for Trico to start working?

Trico is known to be rapidly absorbed by the body, reaching its peak concentration in the bloodstream within a few hours. Official information notes that a clinical response is often observable after a few days of treatment.


Q: What does the research say about Trico's long-term use?

Research evidence for Trico primarily addresses its use for short-course treatment of acute conditions. Official regulatory labeling indicates that use exceeding ten days warrants professional assessment of the potential benefits versus the documented risk of a condition called peripheral neuropathy.


Q: Can Trico affect my mood or sleep?

Official regulatory profiles list trouble sleeping (insomnia) as a possible adverse reaction. The documentation also reports central nervous system effects such as depression and confusion. Severe adverse reactions, including psychotic events, are reported in official documentation when Trico is co-administered with alcohol or Disulfiram.


Q: What are the typical results seen in the research evidence for Trico?

Clinical studies demonstrate that Trico is an established therapy against the susceptible anaerobic bacteria and protozoa it is indicated to treat. Research reports measurements of parasite clearance and resolution of common symptoms for the infections it addresses. These findings support the drug’s use in targeting and eliminating specific infection-causing organisms.


Q: What if Trico doesn't seem to be working for me after the expected time?

Official instructions state that the medication should be taken exactly as directed for the full prescribed time. Although it is common to feel better early in therapy, the full course is necessary. If concerns arise about effectiveness, official instructions indicate that effectiveness concerns should be addressed with the prescribing healthcare professional.


Q: What should I do if I think I'm having a side effect from Trico?

Official labeling states that patients should inform their healthcare professional if they experience symptoms related to nerve damage, such as numbness or tingling. Guidance is also given to seek professional attention if serious central nervous system symptoms, such as seizures, confusion, or severe allergic reactions, occur.


Q: Is it safe to drink coffee or caffeine while taking Trico?

Official labeling mandates the avoidance of alcohol and disulfiram due to documented risks of severe reactions. Other beverages, like coffee or caffeine, are not specifically listed among the mandatory contraindications in the regulatory information.


Q: What is the duration of action for Trico?

The duration of action of Trico in the body is described in the official prescribing information using the concept of elimination half-life. The average elimination half-life of the active ingredient in healthy adults is approximately eight hours. This measurement describes the time it takes for half of the drug to be processed and eliminated.


Q: How long will I need to keep taking Trico?

The duration of treatment with Trico is determined by the specific condition being treated, as set by a healthcare professional. According to the regulatory text, treatment is typically prescribed for 7 to 10 days for most anaerobic infections.


Q: Is Trico available as a generic medicine?

According to regulatory documents, the active ingredient in Trico, metronidazole, is available in the United States as both a brand-name and a generic medicine.


Q: Does Trico cause weight gain or weight loss?

Weight loss is listed as a possible side effect in some official adverse reaction reports documented by regulatory bodies. However, weight gain is not noted in the official common or serious adverse event categories.


Q: How does Trico get eliminated from the body?

Official product information on Trico’s pharmacokinetics confirms that the major route of elimination is through the urine. Between 60% and 80% of the administered dose of the drug and its metabolites are excreted this way.


Q: Is Trico a controlled substance?

Trico (metronidazole) is classified as a prescription-only drug in the United States. It is not listed as a scheduled controlled substance by the Drug Enforcement Administration (DEA).


Q: Can Trico affect my ability to drive or operate machinery?

The drug is associated with central nervous system adverse reactions, including dizziness and ataxia (loss of coordination). Official labeling notes that if these symptoms occur, operating motor vehicles or machinery may need to be suspended.


Q: Why is it important to know who should not use Trico?

Regulatory documents define mandatory contraindications because using the drug in these specific populations is associated with a documented risk of severe adverse reactions, such as hepatotoxicity. This prevents the possibility of a serious safety risk where the medicine is not appropriate.


Q: What does 'contraindication' mean in relation to Trico?

A contraindication describes a condition or circumstance where a medicine is formally excluded from use, as strictly defined in the official safety profile. This is because the documented risks for that population significantly outweigh any possible benefit from the medication.


Q: What is the mechanism of action of Trico, in simple terms?

Trico is classified as a prodrug, which means it needs to be chemically activated to work. This activation happens only within the susceptible bacteria and parasites. Once active, the medicine generates a component that directly damages the organism’s DNA and genetic material, leading to disruption of the organism’s function.


Q: How does the body process Trico after it's taken?

Official information on pharmacokinetics states that Trico is well-absorbed after being taken orally. The drug then distributes throughout the body, is metabolized (broken down) primarily by the liver, and is mostly eliminated through the urine.


Q: Does Trico treat the condition in men the same way it does in women?

Official clinical studies comparing male and female subjects report no significant bioavailability differences (how the drug is absorbed and made available). However, official reports note that due to general body weight differences, the resulting plasma levels in males are often observed to be lower.

How should Trico be stored and disposed of?

Storage and Disposal Requirements for Trico (Metronidazole)

Official labeling defines strict conditions for storing Metronidazole to maintain its stability and effectiveness.

Storage Conditions

Trico must be stored at controlled room temperature, typically 15 C to 25 C (59 F to 77 F). It must be kept in its tightly closed, original container and protected from light, excessive heat, and moisture. It is explicitly required to keep from freezing. Like all medicines, it must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Trico should be managed through an official drug take-back program or disposed of according to local regulations. The medicine must not be flushed down sinks or toilets, but rather mixed with an undesirable substance and sealed before being placed in household trash if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trico found in:

A-Z Index: